CD68 and non-small cell lung carcinoma: An obvious example is lung cancer, in which the CD68+ macrophages’ high attendance in tumor cell islets increases the survival in non-small-cell lung cancer (NSCLC) [12,14,17], while it decreases the survival rate in the lung tumor stroma [12,14,96].